News searcher
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
Summary of the financial results of 2019
6 min
26 Feb, 2020
ROVI announces the commencement of the assessment process to obtain marketing authorisation for Doria® in the European Union
Assessment process to grant marketing authorisation for Doria® in the European Union
2 min
31 Jan, 2020
ROVI updates its strategy in a meeting with shareholders, investors and analysts.
0 min
25 Nov, 2019
Javier López-Belmonte, Vicepresident and CFO of Laboratorios Farmacéuticos ROVI presents the financial results for the...
0 min
25 Nov, 2019
Summary of the financial results for the first nine months of 2019
5 min
07 Nov, 2019
The new plant will manufacture the active substances for low-molecular-weight heparins. To this end, ROVI will invest...
3 min
05 Sep, 2019
Summary of the financial results for the first half of 2019
6 min
30 Jul, 2019
Operating income, growth figures, profitability and how our products have behaved
0 min
30 Jul, 2019
The final results of the pivotal PRISMA-3 study show the efficacy of both dosage strengths of the once-monthly...
5 min
05 Jul, 2019